Companies / HUMA Humacyte, Inc. (HUMA)
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Ticker HUMA Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $125.01M 52-week range $0.34 - $1.52 Valuation Share price $0.45 (close of Nov 6, 2026) P/E (TTM) -0.93x Price to book 4.00x Price to free cash flow -1.28x Enterprise value $111.29M Book value per share $0.11 Price performance Period Change 1 day +12.50% 5 days +9.76% 1 month -6.25% 3 months -36.62% 6 months -54.08% Year to date -53.12% 1 year -65.65% 3 years -80.09% 5 years -95.82% All time -95.35%
Short interest As of Oct 15, 2026 Short % of float 10.95% Shares short 30.25M Days to cover 3.66 Change since prior report +2.90% Source FINRA consolidated short interest Profitability and growth Return on invested capital -159.13% Return on assets -35.09% Return on capital employed -110.35% Gross margin -376.05% Net margin -2,003.58% EBITDA margin -5,044.60% Cash flow and balance sheet Free cash flow yield (TTM) -78.04% Current ratio 6.21x Net debt to EBITDA 0.17x Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $2.04M Cost of revenue $9.70M Gross profit -$7.66M EBITDA -$102.81M Net income -$40.83M Earnings per share $-0.26 Research and development $69.30M Interest expense $11.25M Shares outstanding 158.16M Income statement by year Period end Revenue Gross profit Net income EPS 2025-12-31 $2.04M -$7.66M -$40.83M -$0.26 2024-12-31 - - -$148.70M -$1.26 2023-12-31 - - -$110.78M -$1.07 2022-12-31 - - -$11.96M -$0.12 2021-12-31 - - -$26.48M -$0.66 2020-12-31 - - -$66.52M -$11.54
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 -376.05% -2,003.58% - -159.13% 2022-12-31 - - -10.23% -50.65% 2021-12-31 - - -21.67% -46.14%
Cash and debt by year Period end Cash Debt 2025-12-31 $50.50M $35.44M 2024-12-31 $44.94M - 2023-12-31 $80.40M - 2022-12-31 $151.90M - 2021-12-31 $225.50M $30.00M 2020-12-31 $39.93M - 2019-12-31 $93.71M -
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$105.93M $9.75M 2024-12-31 -$99.69M $6.14M 2023-12-31 -$75.58M $6.83M 2022-12-31 -$72.18M $6.18M 2021-12-31 -$81.41M $10.15M 2020-12-31 -$55.89M $4.69M 2019-12-31 -$79.91M -
Investor relations Next earnings report Next confirmed report Nov 10, 2026 Consensus EPS estimate $-0.09 Past earnings dates Reported Fiscal period EPS estimate 2026-08-12 Jun 2026 -$0.10 2026-05-13 Mar 2026 -$0.10 2026-03-27 Dec 2025 -$0.13 2025-11-12 Sep 2025 -$0.17 2025-08-11 Jun 2025 -$0.15 2025-05-13 Mar 2025 -$0.19 2025-03-28 Dec 2024 -$0.23 2024-11-08 Sep 2024 -$0.26
Filings and sources Company website humacyte.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades